scholarly journals A prospective comparison of common toxicity criteria adverse events Version 3 and 4 in assessing oral mucositis for oral and oropharyngeal carcinoma

2017 ◽  
Vol 1 ◽  
pp. 18-21 ◽  
Author(s):  
M. Hickman ◽  
S.J. Meade ◽  
C. Fong ◽  
P. Sanghera ◽  
J. Good ◽  
...  
Keyword(s):  
Adverse Events ◽  
Oral Mucositis ◽  
Oropharyngeal Carcinoma ◽  
Prospective Comparison ◽  
Oral And Oropharyngeal Carcinoma ◽  
Toxicity Criteria

Outcomes and xerostomia after postoperative radiotherapy for oral and oropharyngeal carcinoma

Head & Neck ◽  
2014 ◽  
pp. n/a-n/a
Author(s):  
Zhong-He Wang ◽  
Chao Yan ◽  
Zhi-Yuan Zhang ◽  
Chen-Ping Zhang ◽  
Hai-Sheng Hu ◽  
...  
Keyword(s):  
Postoperative Radiotherapy ◽  
Oropharyngeal Carcinoma ◽  
Oral And Oropharyngeal Carcinoma

Impact of treatment on quality of life for oral and oropharyngeal carcinoma

2009 ◽  
Vol 38 (10) ◽  
pp. 1052-1058 ◽  
Author(s):  
P. Infante-Cossio ◽  
E. Torres-Carranza ◽  
A. Cayuela ◽  
E. Hens-Aumente ◽  
P. Pastor-Gaitan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Oropharyngeal Carcinoma ◽  
Oral And Oropharyngeal Carcinoma

Validity of sentinel node biopsy in early oral and oropharyngeal carcinoma

2018 ◽  
Vol 46 (10) ◽  
pp. 1748-1752 ◽  
Author(s):  
C.G.U. Riese ◽  
J.-A. Karstadt ◽  
A. Schramm ◽  
S. Güleryüz ◽  
G. Dressel ◽  
...  
Keyword(s):  
Sentinel Node ◽  
Sentinel Node Biopsy ◽  
Oropharyngeal Carcinoma ◽  
Node Biopsy ◽  
Oral And Oropharyngeal Carcinoma

NCMP-14. WHOLE BRAIN RADIOTHERAPY COMBINED WITH INTRATHECAL LIPOSOMAL CYTARABINE FOR LEPTOMENINGEAL METASTASIS – A SAFETY ANALYSIS AND VALIDATION OF THE EANO-ESMO CLASSIFICATION

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi149-vi150
Author(s):  
Sarah Iglseder ◽  
Martha Nowosielski ◽  
Gabriel Bsteh ◽  
Armin Muigg ◽  
Johanna Heugenhauser ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Adverse Events ◽  
Treatment Response ◽  
Diagnostic Criteria ◽  
Radiation Therapy Oncology Group ◽  
Safety Analysis ◽  
Liposomal Cytarabine ◽  
Csf Cytology ◽  
Whole Brain ◽  
Toxicity Criteria

Abstract BACKGROUND Although there is no proven standard therapy for leptomeningeal metastases (LM), treatment often includes intrathecal chemotherapy combined with whole brain radiation therapy (WBRT). Little is known on the toxicity of such combination therapies. We performed a retrospective safety analysis for the combination of intrathecal liposomal cytarabine with WBRT in patients with LM and validated the EANO-ESMO classification in this unique cohort. METHODS Treatment toxicities in patients diagnosed with LM between 2004 and 2014 were retrospectively analyzed according to the RTOG (Radiation Therapy Oncology Group) and NCI CTCAE V5.0 (Common Toxicity Criteria Adverse Events) toxicity criteria. Diagnostic criteria and treatment response as assessed by EANO-ESMO classification were correlated with survival by Kaplan Meier analysis and Breslow test. RESULTS 40 patients with LM who were treated with combined WBRT and intrathecal cytarabine, were identified. Ten patients (25%) experienced adverse events ≥ grade 3 according to the RTOG-toxicity criteria, in 22 patients (55%) CTCAE criteria ≥3 grade were detected. Median overall survival (mOS) was 124.0 days [72.9;175.1]. Median time to neurological progression was 52.0 days [41.1; 62.8]. When comparing the diagnostic criteria, patients with a positive CSF cytology (n=26) showed worse prognosis compared to patients with a negative CSF cytology (n=14) (mOS 84 days [44.0;124.0] versus 198.0 days [162.6;233.4] days, p=0.006, respectively). The EANO-ESMO response assessment correlated significantly with survival - “stable” (n=7) mOS 233.0 [76.5;389.5] days, “response” (n=10) mOS 206.0 [193.9;218.9] days, “progression” (n=17) mOS 45.0 [34.4;55.6] days, “suspicion of progression” (n=6) mOS 133.0 [65.8;200.2] days (overall, p< 0.001). CONCLUSIONS In this retrospective analysis, the treatment combination of WBRT and intrathecal liposomal cytarabine shows an acceptable safety profile. The EANO-ESMO classification for diagnosis and treatment response predicts survival

scholarly journals Effect ofKangfuxinSolution on Chemo/Radiotherapy-Induced Mucositis in Nasopharyngeal Carcinoma Patients: A Multicenter, Prospective Randomized Phase III Clinical Study

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Yangkun Luo ◽  
Mei Feng ◽  
Zixuan Fan ◽  
Xiaodong Zhu ◽  
Feng Jin ◽  
...  
Keyword(s):  
Clinical Study ◽  
Nasopharyngeal Carcinoma ◽  
Adverse Events ◽  
Oral Mucositis ◽  
Rating Scale ◽  
Test Group ◽  
Phase Iii ◽  
Control Group ◽  
Oral Pain ◽  
Gastrointestinal Mucositis

Objective. To evaluate the efficacy and safety ofKangfuxinSolution, a pure Chinese herbal medicine, on mucositis induced by chemoradiotherapy in nasopharyngeal carcinoma patients.Methods. A randomized, parallel-group, multicenter clinical study was performed. A total of 240 patients were randomized to receive eitherKangfuxinSolution (test group) or compound borax gargle (control group) during chemoradiotherapy. Oral mucositis, upper gastrointestinal mucositis, and oral pain were evaluated by Common Terminology Criteria for Adverse Events (CTCAE) v3.0 and the Verbal Rating Scale (VRS).Results. Of 240 patients enrolled, 215 were eligible for efficacy analysis. Compared with the control group, the incidence and severity of oral mucositis in the test group were significantly reduced (P=0.01). The time to different grade of oral mucositis occurrence (grade 1, 2, or 3) was longer in test group (P<0.01), and the accumulated radiation dose was also higher in test group comparing to the control group (P<0.05). The test group showed lower incidence of oral pain and gastrointestinal mucositis than the control group (P<0.01). No significant adverse events were observed.Conclusion.KangfuxinSolution demonstrated its superiority to compound borax gargle on mucositis induced by chemoradiotherapy. Its safety is acceptable for clinical application.

Acute Enterocolitis Incidence in Patients with Hematological Malignancies Receiving Myelotoxic Therapy Requiring Hematopoietic Stem Cell Support - Palifermin Experience.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 5461-5461
Author(s):  
Isabel Sousa ◽  
Catarina Geraldes
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Adverse Events ◽  
Stem Cell Transplantation ◽  
Parenteral Nutrition ◽  
Hematopoietic Stem Cell ◽  
Oral Mucositis ◽  
Hematological Malignancies ◽  
Control Group ◽  
Hematopoietic Stem

Abstract Background: Chemotherapeutic agents can cause severe oral and gastrointestinal mucositis, for which there is currently no treatment. Previous research demonstrates that palifermin - keratinocyte growth factor - is potentially antimucotoxic, reducing the duration and severity of oral mucositis after intense chemotherapy in hematological cancers. The primary aim of this study was to determine palifermin effectiveness in ameliorating chemotherapy-induced diarrhoea and oral mucositis incidence. Palifermin adverse events were also assessed. Methods: Retrospective observational study involving patients with hematological malignancies undergoing autologous hematopoietic stem-cell transplantation after myelotoxic therapy. All the patients received antibiotic, antifungal, and antiviral prophylaxis. Patients being treated with palifermin to decrease the incidence and duration of severe oral mucositis (Palifermin Group) were compared to a control group of patients who did not receive palifermin (Control Group). Palifermin was administered during 3 consecutive days, before and after myelotoxic therapy in a 60 μg/Kg daily intravenous dose. Results: Twenty-four patients were included, 8 in Palifermin Group and 16 in Control Group. Baseline malignancies were Hodgkin and non Hodgkin lymphoma, acute myeloid leukemia, and multiple myeloma. All patients underwent autologous hematopoietic stem-cell transplantation after the following conditioning regimes: BEAM, BuCy, and Mel200 respectively. In Palifermin Group, 62.5% were male, mean age 47.6±13.0 years, mean disease duration of 22.3±10.1 months (N=8). In Control Group 56.3% were male, mean age 45.8±12.1 years (N=16). Mean performance status (Karnofsky Index) was 80±14.1% and 71.3±15.1%, in each group, respectively. No statistically significant differences between Palifermin and Control Groups were found regarding the degree of diarrhoea, although in the Palifermin Group the majority of patients presented a grade 2 (N=3) and in the Control Group a grade 3 (N=6). In the Palifermin Group there was a tendency for a lower incidence of hypoalbuminemia [12.5% (Palifermin Group) vs. 50% (Control Group)], which corresponded to a significant lower difference in the needs for receiving parenteral nutrition (P=0.011). Nevertheless, these findings were not translated in less febrile episodes or less iv antibiotic therapy days. There were no significant differences between the two groups regarding the degree of oral mucositis, the number of days of analgesic opioids use, and the number of hospitalization days, most probably due to the small sample considered. The most common adverse events in the Palifermin Group were reversible erythema and edema of the face and upper trunk that have occurred only in 3 patients. Weight increase was mild and similar in both groups of patients [Median weight increase±SD: 1,0±1,7 Kg (Palifermin Group) vs 2,0±2,5 Kg (Control group)]. Conclusion: Gastrointestinal and oral mucositis are common consequences of cancer therapy with a direct and significant impact on the quality of life and care costs, also affecting patient’s survival. Our exploratory study shows that palifermin treatment is well tolerated, potentially reducing diarrhoea and the incidence of hypoalbuminemia, and significantly reducing the needs for parenteral nutrition. However further studies with an increased number of patients will be necessary to provide more evidence concerning palifermin efficacy in the management of these cancer therapy’s debilitating side-effects.

Expression of hMSH2 correlates with in vitro chemosensitivity to CDDP cytotoxicity in oral and oropharyngeal carcinoma

1998 ◽  
Vol 132 (1-2) ◽  
pp. 37-44 ◽  
Author(s):  
Shigeharu Fujieda ◽  
Nobuyuki Tanaka ◽  
Hiroshi Sunaga ◽  
Ichiro Noda ◽  
Chizuru Sugimoto ◽  
...  
Keyword(s):  
Oropharyngeal Carcinoma ◽  
In Vitro Chemosensitivity ◽  
Oral And Oropharyngeal Carcinoma

Evaluation of Immunohistochemical Expression of p16 and Presence of Human Papillomavirus in Oral and Oropharyngeal Carcinoma

2014 ◽  
Vol 25 (1) ◽  
pp. 210-214 ◽  
Author(s):  
Ana Luíza Laguardia Cantarutti ◽  
Lais Papini Fernandes ◽  
Marina Vaz de Lima Fullin Saldanha ◽  
Ana Elizia Mascarenhas Marques ◽  
Leonora Maciel de Souza Vianna ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Oropharyngeal Carcinoma ◽  
Immunohistochemical Expression ◽  
Oral And Oropharyngeal Carcinoma
Sign in / Sign up

Export Citation Format

Share Document